Summary. A 26 year old woman with fasting spontaneous hypoglycaemia and organic hyperinsulinism (probable insulinoma) who had obtained no improvement after a 2/3 panereatectomy was treated for over a year with Chlorpromazine (50 mg/day). The treatment has considerably increased the fasting blood glucose level and has significantly lowered the basal insulin concentrations. After an oral glucose load insulin secretion appeared to be clearly reduced when compared to the pre-treatment values. Nausea and hirsutism which had become evident during a previous treatment with Diazoxide, disappeared completely on Chlorpromazine. Furthermore no important side effects were noted. The role of Chlorpromazine in the treatment of organic hyperinsulinism is discussed.
The choice of drugs presently available for the effective prevention of hypoglycaemia secondary to endogenous hyperinsulinaemia in patients with presumed but surgically not proven benign islet-cell adenomas is limited to Diazoxide administered alone or in association with thiazide-diuretics [1], glueocortieoids or glucagon. Since Diazoxide is frequently ineffective at dosage levels tolerated by the patients and since the use of betaeytotoxie agents such as Streptozotocin is precluded in eases without proven metastatic malignancy, a therapeutic alternative or complement to Diazoxide is desirable for the use in patients intolerant or unresponsive to Diazoxide.
t{eports of hyperglyeaemia and of non-ketotie hyperglycaemic coma occurring in patients treated with Chlorpromazine (CPZ) for psychiatric reasons [2, 3] , the recent observation of an inhibitory effect of CPZ on glucose-induced insulin release in rat islets of Langerhans in vitro [4, 5] and a preliminary communication suggesting a favorable effect of CPZ in a patient with islet cell carcinoma [6] have prompted the authors to use CPZ in a patient suffering from organic hyperinsulinism in whom operation failed to improve the persistent tendency to hypoglyeaemia. Although Diazoxide alleviated the hypoglyeaemic attacks and reduced the concentrations of circulating insulin, an alternative mode of treatment had to be sought since at effective dose levels, the drug induced persistent nausea and eosmetically intolerable hirsutism and since the patient and her family refused further investigation or a second surgical intervention. 
Case History
In 1969 C.A., a previously healthy 26 year old woman, began to exhibit episodes of abnormal behaviour accompanied by tremor and seizures without loss of consciousness in the morning before breakfast.
tIypoglycaemia was suspected and in January 1971 the patient was admitted to this hospital. Fasting blood glucose concentration (glucose-oxidase) varied between 19 and 43 rag/100 ml (mean 31 rag/100 m]). Fasting plasma insulin (It~I; Hales and Randle) level oscillated between 65 and 260 ~U/ml (mean 162 ~U/ml). During a tolbutamide and a leucine tolerance test excessive It~I-responses, profond hypoglycaemia and coma occurred; after glueagon i.v. (1 rag) plasma insulin rose from 65 to 330 ~U/ml.
Appropriate tests failed to reveal abnormal function of the hypophysis, adrenals, thyroid or liver. A diagnosis of an insulin producing pancreatic tumor was made. In April 1971 laparatomy was performed. No pancreatic or extrapancreatic abdominal tumor was detected. A 2/3 panereatectomy was performed. Subsequent careful histological scrutiny of the removed tissue failed to reveal an adenoma or diffuse islet hyperplasia or hypertrophy. The operation resulted in no improvement of the patients condition, in that hypoglycaemic attacks continued to occur and plasma II~I concentrations remained unchanged. Treatment with Diazoxide (300 mg/day) and Bendroflumethiazide (5rag/day) was started. Fasting blood glucose concentrations rose immediately and plasma insulin fell to about 1/3 of the values measured before treatment but remained elevated above normal level (mean~=S D:19~7 [xU/ml) ( Table 1 ). The hypoglycaemic attacks subsided with the exception of an occasional feeling of dizziness. Subsequently she experienced persistent nausea and developed cosmetically disturbing hirsutism. For these reasons Diazoxide and Bendroflumethiazide were discontinued and the patient received Chlorpromazine as from December 1971.
The results obtained with CI~Z appear encouraging, but the mechanism by which this drug exerted its favorable effect in this patient have not been studied in detail. The number of estimations is reported between parentheses.
The dose was progressively increased from 25 to 75 rag/day, at which dose the patient complained of slight somnolence during the day. A maintenance dose of 50 mg/day was the given. As shown by the data presented in Table i , blood glucose concentrations were slightly lower and plasma Ii~I values slightly higher than those measured while the patient received Diazoxide. Despite this, the patients condition improved dramatically, nausea and hirsutism disappeared completely. No hypoglycaemie attacks occurred and the episodes of slight dizziness did not occur more frequently than with Diazoxide. The patient felt completely well and refused further investigation or another operation. One year after the beginning of the CPZ treatment an oral glucose tolerance test (100 g in 200 ml lemonade) was performed in order to obtain a comparison with an identical test performed before the start of the Diazoxide treatment. The results of both tests are represented in Fig. 1 and show that, apart from the low basal glucose concentration and the elevated I1~I value at 0 min, the curves obtained under CPZ were practically normal and clearly different from those obtained before the onset of treatment.
Discussion
Although we were unable to prove the existence of an insulinoma in this patient, continuous fasting hyperinsulinaemia as well as excessive IRI-responses to leucine, tolbutamide and glueagon argue strongly in favor of this clinical diagnosis. The existence of pancreatic malignancy can be ruled out on basis of the duration of the disease and in view of the patients excellent state of health which persists up to now. Unfortunately the patient refuses both further investigation in order to localize and to remove her adenoma and a controlled attempt to withdraw treatment.
Ammon and Steinke [4] and Orci et al. [5] have shown that, in isolated islets of Langerhans from the rat, C1)Z interferes with glucose-induced insulin release and causes a dose-dependent increase in the number of autophagosomes in the fi-cells. Although the concentrations used in vitro by these workers are likely to be higher than those achieved in the islets of Langerhans of our patient with a dose of 50 mg/day, and although other possible effects of the drug on glucose metabolism have not been excluded, impairment of insulin secretion by the abnormal islet tissue appears to have been an important, possibly the principal factor responsible for the favorable response to treatment with CPZ. Indeed, and as evidenced by the data shown in table 1 and figure l, a considerable reduction of both basal and glucose-induced insulin secretion occurred under the treatment and persisted for a prolonged period of time.
As judged from the biological data obtained in our patient (Table 1) , CPZ, at the dose used, appears to be less effective in suppressing insulin secretion than Diazoxide (300 mg/day) in association with a thiazide-diuretic. The higher dose (75 mg/day) could not be given long enough to allow satisfactory evaluation.
Moreover, since CPZ, unlike Diazoxide, at the maintenance dose chosen was completely devoid of side effects, its therapeutic efficiency was considered superior to that of Diazoxide by both patient and physicians. It is therefore thought that CPZ should be tested as a potentially useful alternative to Diazoxide in the treatment of endogenous hyperinsulinism, and that its clinical usefulness in the various pathogenetic forms of this condition should be tested and defined.
